MCM
ANIK icon

Mainstay Capital Management’s Anika Therapeutics ANIK Stock Holding History

Mainstay Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,042
Closed -$171K – 104
2018
Q3 		$171K Buy
4,042
+65
+2% +$2.57K 0.11% 104
2018
Q2 		$127K Buy
3,977
+395
+11% +$16.3K 0.1% 102
2018
Q1 		$178K Buy
3,582
+240
+7% +$13.6K 0.14% 96
2017
Q4 		$180K Buy
+3,342
New +$185K 0.15% 101

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Mainstay Capital Management's ANIK Position: Q4 2018 in Review

Mainstay Capital Management sold out of Anika Therapeutics (ANIK) in Q4 2018, closing a stake of 4,042 shares — an estimated $171K sold.

Mainstay Capital Management first reported a position in ANIK in Q4 2017 and held it in 4 quarters. The position peaked at $180K in Q4 2017. 162 funds tracked by Wall St. Rank hold ANIK as of Q4 2018.

  • Mainstay Capital Management reported no remaining Anika Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Mainstay Capital Management sold 4,042 Anika Therapeutics shares in Q4 2018, an estimated $171K.
  • Mainstay Capital Management first reported a position in Anika Therapeutics in Q4 2017 and held it in 4 quarters.
  • Mainstay Capital Management's Anika Therapeutics position peaked at $180K in Q4 2017.
  • 162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2018.

Based on Mainstay Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.